Literature DB >> 29556840

Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Monique Piraud1, Magali Pettazzoni2, Pamela Lavoie3, Séverine Ruet2, Cécile Pagan2, David Cheillan2, Philippe Latour4, Christine Vianey-Saban2, Christiane Auray-Blais3, Roseline Froissart2.   

Abstract

Tandem mass spectrometry (MS/MS) is a highly sensitive and specific technique. Thanks to the development of triple quadrupole analyzers, it is becoming more widely used in laboratories working in the field of inborn errors of metabolism. We review here the state of the art of this technique applied to the diagnosis of lysosomal storage disorders (LSDs) and how MS/MS has changed the diagnostic rationale in recent years. This fine technology brings more sensitive, specific, and reliable methods than the previous biochemical ones for the analysis of urinary glycosaminoglycans, oligosaccharides, and sialic acid. In sphingolipidoses, the quantification of urinary sphingolipids (globotriaosylceramide, sulfatides) is possible. The measurement of new plasmatic biomarkers such as oxysterols, bile acids, and lysosphingolipids allows the screening of many sphingolipidoses and related disorders (Niemann-Pick type C), replacing tedious biochemical techniques. Applied to amniotic fluid, a more reliable prenatal diagnosis or screening of LSDs is now available for fetuses presenting with antenatal manifestations. Applied to enzyme measurements, it allows high throughput assays for the screening of large populations, even newborn screening. The advent of this new method can modify the diagnostic rationale behind LSDs.

Entities:  

Keywords:  Biomarkers; Lysosomal storage diseases; Tandem mass spectrometry

Mesh:

Substances:

Year:  2018        PMID: 29556840     DOI: 10.1007/s10545-017-0126-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  199 in total

1.  Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.

Authors:  K Oberholzer; A C Sewell
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

2.  LC-MS/MS based assay and reference intervals in children and adolescents for oxysterols elevated in Niemann-Pick diseases.

Authors:  Glynis Klinke; Marianne Rohrbach; Roberto Giugliani; Patricie Burda; Matthias R Baumgartner; Christel Tran; Matthias Gautschi; Déborah Mathis; Martin Hersberger
Journal:  Clin Biochem       Date:  2015-03-25       Impact factor: 3.281

3.  Clinical, morphological, and molecular aspects of sialic acid storage disease manifesting in utero.

Authors:  R Froissart; D Cheillan; R Bouvier; S Tourret; V Bonnet; M Piraud; I Maire
Journal:  J Med Genet       Date:  2005-04-01       Impact factor: 6.318

4.  A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.

Authors:  Haoyue Zhang; Tim Wood; Sarah P Young; David S Millington
Journal:  Mol Genet Metab       Date:  2014-10-05       Impact factor: 4.797

5.  Analytical method for keratan sulfates by high-performance liquid chromatography/turbo-ionspray tandem mass spectrometry.

Authors:  T Oguma; H Toyoda; T Toida; T Imanari
Journal:  Anal Biochem       Date:  2001-03-01       Impact factor: 3.365

6.  Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  Trisha A Duffey; Martin Sadilek; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Anal Chem       Date:  2010-10-20       Impact factor: 6.986

7.  Sialic acid storage disease with sialuria: clinical and biochemical features in the severe infantile type.

Authors:  R E Stevenson; M Lubinsky; H A Taylor; D A Wenger; R J Schroer; P M Olmstead
Journal:  Pediatrics       Date:  1983-10       Impact factor: 7.124

Review 8.  A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.

Authors:  L van der Tol; B E Smid; B J H M Poorthuis; M Biegstraaten; R H Lekanne Deprez; G E Linthorst; C E M Hollak
Journal:  J Med Genet       Date:  2013-08-06       Impact factor: 6.318

9.  Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Authors:  C Auray-Blais; D S Millington; S P Young; J T R Clarke; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-01-26       Impact factor: 4.982

10.  Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study.

Authors:  Richard W D Welford; Marco Garzotti; Charles Marques Lourenço; Eugen Mengel; Thorsten Marquardt; Janine Reunert; Yasmina Amraoui; Stefan A Kolb; Olivier Morand; Peter Groenen
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

View more
  3 in total

1.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.

Authors:  Shaukat A Khan; Robert W Mason; Roberto Giugliani; Kenji Orii; Toshiyuki Fukao; Yasuyuki Suzuki; Seiji Yamaguchi; Hironori Kobayashi; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-17       Impact factor: 4.797

Review 2.  Niemann-Pick type C disease: The atypical sphingolipidosis.

Authors:  Jason Newton; Sheldon Milstien; Sarah Spiegel
Journal:  Adv Biol Regul       Date:  2018-08-28

3.  Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry.

Authors:  Justin Mak; Tina M Cowan
Journal:  Mol Genet Metab       Date:  2021-08-21       Impact factor: 4.204

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.